iSonea rapidly approaches commercialisation, targets US$16 billion asthma market – Proactive Investors UK


mobihealthnews

iSonea rapidly approaches commercialisation, targets US$16 billion asthma market
Proactive Investors UK
iSonea (ASX: ISN) is preparing to roll out a number of its asthma products over the next 24 months after entering its first formal partnership with telecommunications company Qualcomm Life for the development of a mobile asthma monitoring platform.
iSonea to Develop New Asthma Mobile Health Technology Based on Qualcomm 2net HubMarketWatch (press release)
Qualcomm Life, iSonea to offer mobile asthma monitormobihealthnews
iSonea gains partner to develop new mobile asthma monitoring systemProactive Investors USA & Canada

all 15 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.